7/24/2019 6:47 PM

Every Other Day Antiretroviral Maintenance Strategy

7/24/2019 6:44 PM

The Future: Islatravir

7/24/2019 6:39 PM

Dolutegravir and Neural Tube Defects

7/24/2019 6:29 PM

Two-drug Regimens May Be Better Than Three… Depending on the Drugs

7/24/2019 3:19 PM

New Antiretrovirals: Challenging the Status Quo

7/23/2019 11:00 PM

Event Driven PrEP (ED-PrEP) – Another Prevention Option

7/23/2019 10:41 PM

Event Driven PrEP: Science and the Prévenir Study

7/23/2019 9:32 PM

IAS Mexico City Late-breaker: Once-a-year PrEP Implant in Development

7/22/2019 10:24 PM

Long-acting IM Cabotegravir + Rilpivirine: More Popular than Conventional Oral Regimens

7/22/2019 9:54 PM

IAS Mexico City: Monthly IM Cabotegravir + Rilpivirine Non-inferior to Oral ART

10/23/2018

HIV Pathogenesis Re-defined, Up-close and in Real-time

10/22/2018

HIV Research for Prevention (HIVR4P) 2018 in Madrid: We Need More Choices!

7/30/2018

Increased PrEP Use = Fewer New HIV Infections, United States

07/30/2018

PrEP On Demand: Infections Averted

7/30/2018

The PARTNER 2 Study and Undetectable = Untransmittable (U=U)

7/30/2018

Interactions between Feminizing Hormones and PrEP among Transgender Women

7/30/2018

AIDS 2018 in Amsterdam

08/07/17

8 is the New 12: Shorter Treatment for HCV Coinfection

08/07/17

Keeping Watch for Drug-Drug Interaction, HBV Reactivation, and HCC during HCV Treatment

08/07/17

Can We Treat HCV Away? Eliminating HCV among HIV-positive Men in Amsterdam

08/07/17

How Quickly Can Hepatitis C Be Cured?

02/14/2017

We Need Decreases in New HIV Infection in All At-risk Populations, Not Just Some

02/14/2017

Treatment IS Prevention